<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02191930</url>
  </required_header>
  <id_info>
    <org_study_id>B-CAP</org_study_id>
    <nct_id>NCT02191930</nct_id>
  </id_info>
  <brief_title>Brentuximab Vedotin or B-CAP in the Treatment of Older Patients With Newly Diagnosed Classical Hodgkin Lymphoma</brief_title>
  <acronym>B-CAP</acronym>
  <official_title>Brentuximab Vedotin or B-CAP in the Treatment of Older Patients With Newly Diagnosed Classical Hodgkin Lymphoma - a GHSG-NLG Intergroup Phase II Trial -</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Cologne</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Cologne</source>
  <brief_summary>
    <textblock>
      The purpose of this trial is to determine

        1. Objective response rate (ORR), defined as the proportion of patients having CR, CRr or
           PR in the centrally reviewed restaging after six cycles of chemotherapy

        2. Progression-free survival (PFS) 3 years after registration
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 2015</start_date>
  <completion_date type="Anticipated">October 2018</completion_date>
  <primary_completion_date type="Anticipated">May 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective response rate</measure>
    <time_frame>after 6 cycles of therapy (at least 18 weeks after start of treatment)</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">70</enrollment>
  <condition>Hodgkin Lymphoma</condition>
  <arm_group>
    <arm_group_label>B-CAP</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with ECOG of 2 or less (3 or less if caused by HL) and CIRS-G score of 6 or less (overall) and 3 or less per organ system receive 6 cycles of B-CAP (Brentuximab vedotin, cyclophosphamide, doxorubicine, predniso(lo)ne). Cycle length is 21 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Brentoximab Vedotin only</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with CIRS-G score of 7 ore more receive Brentuximab Vedotin as single agent therapy for up to 16 cycles. Cycle length is 21 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>B-CAP</intervention_name>
    <arm_group_label>B-CAP</arm_group_label>
    <other_name>Brentuximab Vedotin</other_name>
    <other_name>Cyclophosphamide</other_name>
    <other_name>Doxorubicine</other_name>
    <other_name>Predniso(lo)ne</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Brentuximab Vedotin</intervention_name>
    <arm_group_label>Brentoximab Vedotin only</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria (B-CAP):

          -  classical Hodgkin Lymphoma

          -  Age 60 years or older

          -  ECOG performance status ≤ 2 or ≤ 3 if due to HL

          -  CIRS-G score of ≤ 6 and ≤ 3 per organ system (except score 4 for eye, ear, nose and
             throat)

          -  Advanced stages: Stage IIB with large mediastinal mass and/or extranodal lesions,
             stage III or IV disease

          -  written informed consent

        Exclusion Criteria (B-CAP):

          -  Composite lymphoma or nodular lymphocyte- predominant Hodgkin lymphoma (NLPHL)

          -  Prior chemotherapy or radiation for HL except prephase

          -  Peripheral neuropathy greater than CTC Grade 1

        Inclusion Criteria (BV only):

          -  classical Hodgkin Lymphoma

          -  Age 60 years or older

          -  stage IA to IVB

          -  CIRS-G score of ≥ 7 or 4 in one organ system (except score 4 for eye, ear, nose and
             throat)

          -  Patients not eligible to curative poly-chemotherapy at the investigators judgment

          -  written informed consent

        Exclusion Criteria (BV only):

          -  Composite lymphoma or nodular lymphocyte- predominant Hodgkin lymphoma (NLPHL)

          -  Prior chemotherapy or radiation for HL except prephase as outlined in the protocol

          -  Peripheral neuropathy greater than CTC Grade 1
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Peter Borchmann, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital of Cologne</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Michael Fuchs</last_name>
    <email>ghsg@uk-koeln.de</email>
  </overall_contact>
  <location>
    <facility>
      <name>1st Dept. of Medicine, Cologne University Hospital</name>
      <address>
        <city>Cologne</city>
        <zip>50924</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Fuchs</last_name>
      <email>ghsg@uk-koeln.de</email>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>http://www.ghsg.org</url>
    <description>Homepage GHSG</description>
  </link>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 11, 2014</study_first_submitted>
  <study_first_submitted_qc>July 14, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 16, 2014</study_first_posted>
  <last_update_submitted>November 7, 2017</last_update_submitted>
  <last_update_submitted_qc>November 7, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 8, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Cologne</investigator_affiliation>
    <investigator_full_name>Prof. Dr. Peter Borchmann</investigator_full_name>
    <investigator_title>Prof.</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Hodgkin Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

